Filters close
Newswise: Molecular ‘super-glue’ shows promise of cancer drug discovery platform
Released: 16-Jan-2024 12:05 PM EST
Molecular ‘super-glue’ shows promise of cancer drug discovery platform
St. Jude Children's Research Hospital

Scientists at St. Jude Children’s Research Hospital collaborated to identify and improve a chemical compound that acts as a molecular “super-glue” with broad activity across cancers.

Newswise: HOXA9 tracking reveals RBM5 dual function and therapeutic potential for acute myeloid leukemia
Released: 12-Jan-2024 2:05 PM EST
HOXA9 tracking reveals RBM5 dual function and therapeutic potential for acute myeloid leukemia
St. Jude Children's Research Hospital

Using CRISPR/Cas9, scientists at St. Jude Children’s Research Hospital identified RBM5 as a vital component of leukemia cell fitness, making it a promising target for drug development.

Newswise: Two common biomarkers predict heart risk in asymptomatic childhood cancer survivors
Released: 12-Jan-2024 1:05 PM EST
Two common biomarkers predict heart risk in asymptomatic childhood cancer survivors
St. Jude Children's Research Hospital

Scientists at St. Jude Children’s Research Hospital found that two common biomarkers could predict cardiomyopathy that is otherwise undetected by conventional screenings in childhood cancer survivors.

Newswise: Updated genomic landscape for pediatric acute myeloid leukemia enables new treatment possibilities
Released: 11-Jan-2024 11:05 AM EST
Updated genomic landscape for pediatric acute myeloid leukemia enables new treatment possibilities
St. Jude Children's Research Hospital

Scientists at St. Jude Children’s Research Hospital refined and enhanced the classification system for a type of pediatric leukemia using genomic and transcriptomic analysis.

Newswise: Acute pediatric critical illness definition enables global research
Released: 8-Jan-2024 12:05 PM EST
Acute pediatric critical illness definition enables global research
St. Jude Children's Research Hospital

Scientists at St. Jude Children’s Research Hospital collaborated with a global group to create a more inclusive and standardized criterion for acute pediatric critical illness, with implications for improving care.

Newswise: A new approach can address antibiotic resistance to Mycobacterium abscessus
Released: 5-Jan-2024 11:05 AM EST
A new approach can address antibiotic resistance to Mycobacterium abscessus
St. Jude Children's Research Hospital

Scientists at St. Jude Children’s Research Hospital created analogs of the antibiotic spectinomycin that are significantly more effective against these highly resistant bacteria.

Newswise: Elusive cytonemes guide neural development, provide signaling ‘express route’
Released: 2-Jan-2024 11:05 AM EST
Elusive cytonemes guide neural development, provide signaling ‘express route’
St. Jude Children's Research Hospital

Discover the first images of cytonemes during mammalian neural development, serving as express routes to establish morphogen gradients and tissue patterning.

Newswise: GPCR structure: Research reveals molecular origins of function for a key drug target
Released: 21-Dec-2023 3:05 PM EST
GPCR structure: Research reveals molecular origins of function for a key drug target
St. Jude Children's Research Hospital

Scientists at St. Jude Children’s Research Hospital reveal how G protein-coupled receptors, major therapeutic drug targets, decode critical properties of their ligands.

Newswise: Structures of Parkinson’s disease-linked proteins offer a framework for understanding how they work together
Released: 21-Dec-2023 3:05 PM EST
Structures of Parkinson’s disease-linked proteins offer a framework for understanding how they work together
St. Jude Children's Research Hospital

Scientists at St. Jude Children’s Research Hospital used cryo-electron microscopy to characterize the interaction of two proteins implicated in Parkinson’s disease.

Newswise: Unraveling predisposition in bilateral Wilms tumor
Released: 18-Dec-2023 11:05 AM EST
Unraveling predisposition in bilateral Wilms tumor
St. Jude Children's Research Hospital

Scientists at St. Jude Children’s Research Hospital identified genetic and epigenetic mechanisms driving predisposition to this childhood kidney cancer, impacting care and treatment.

Newswise: Prediabetes treatment may reduce heart and kidney risks in childhood cancer survivors
13-Dec-2023 12:05 PM EST
Prediabetes treatment may reduce heart and kidney risks in childhood cancer survivors
St. Jude Children's Research Hospital

Childhood cancer survivors have a higher prevalence of prediabetes and diabetes, which increases their risk of serious disease but also offers opportunities for prevention.

Released: 6-Dec-2023 10:05 AM EST
St. Jude research featured at the American Society of Hematology Annual Meeting
St. Jude Children's Research Hospital

St. Jude researchers will participate in multiple oral and poster presentations and education sessions as well as moderate panels during the ASH conference.

Newswise: Modular chimeric cytokine receptors improve CAR T–cell therapy for solid tumors
Released: 30-Nov-2023 11:05 AM EST
Modular chimeric cytokine receptors improve CAR T–cell therapy for solid tumors
St. Jude Children's Research Hospital

Adding a modular chimeric cytokine receptor to CAR T cells increased their efficacy. Learn how this modular system could improve brain and solid tumor therapy.

   
Newswise: St. Jude revealed functional targets of oncogenic HOXA9 in high-risk pediatric leukemia
Released: 28-Nov-2023 11:05 AM EST
St. Jude revealed functional targets of oncogenic HOXA9 in high-risk pediatric leukemia
St. Jude Children's Research Hospital

Scientists at St. Jude Children’s Research Hospital identified target genes bound and regulated by HOXA9, a protein overexpressed in high-risk leukemia, extending understanding and opening new possibilities for treatment.

Newswise: Promising target for CAR T cells helps cancer trick the immune system
Released: 21-Nov-2023 11:05 AM EST
Promising target for CAR T cells helps cancer trick the immune system
St. Jude Children's Research Hospital

Immunotherapy using modified chimeric antigen receptor (CAR) T cells has greatly improved survival rates for relapsed and recurrent pediatric leukemia and lymphomas, but not brain and solid tumors.

Newswise: Robust chromatin map explains heterogeneity of pediatric acute lymphoblastic leukemia
Released: 20-Nov-2023 10:05 AM EST
Robust chromatin map explains heterogeneity of pediatric acute lymphoblastic leukemia
St. Jude Children's Research Hospital

Scientists at St. Jude Children’s Research Hospital mapped the difference in chromatin accessibility and regulation in different pediatric acute lymphoblastic leukemia subtypes.

Newswise: Fusion oncoprotein forces cell fates toward rhabdomyosarcoma
Released: 15-Nov-2023 12:05 PM EST
Fusion oncoprotein forces cell fates toward rhabdomyosarcoma
St. Jude Children's Research Hospital

Scientists at St. Jude Children’s Research Hospital showed that a fusion oncoprotein can drive molecularly indistinguishable rhabdomyosarcomas arising from both muscle and blood vessel cells.

Newswise: St. Jude scientists identify T-cell differentiation nodes to improve cancer-killing
Released: 15-Nov-2023 11:05 AM EST
St. Jude scientists identify T-cell differentiation nodes to improve cancer-killing
St. Jude Children's Research Hospital

St. Jude scientists mapped the gene regulatory networks responsible for progressive differentiation states of tumor-infiltrating T cells, using a technology known as single-cell CRISPR screening to knock out or genetically perturb multiple genes potentially involved.

Newswise: Giles Robinson, M.D., named director of the Neuro-Oncology Division at St. Jude Children’s Research Hospital
Released: 7-Nov-2023 10:00 AM EST
Giles Robinson, M.D., named director of the Neuro-Oncology Division at St. Jude Children’s Research Hospital
St. Jude Children's Research Hospital

He has also become co-leader of the Neurobiology and Brain Tumor Program within the St. Jude Comprehensive Cancer Center. These combined units comprise one of the largest clinical brain tumor programs in North America.



close
0.13328